|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer Statistics. CA Cancer J Clin. 59:225–249. 2009.
|
|
2
|
Varadhachary GR, Tamm EP, Abbruzzese JL,
Xiong HQ, Crane CH, Wang H, Lee JE, Pisters PW, Evans DB and Wolff
RA: Borderline resectable pancreatic cancer: definitions,
management, and role of preoperative therapy. Ann Surg Oncol.
13:1035–1046. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yip D, Karapetis C, Strickland A, Steer CB
and Goldstein D: Chemotherapy and radiotherapy for inoperable
pancreatic cancer. Cochrane Database Syst Rev. 3:CD0020932006.
|
|
4
|
Sultana A, Tudur Smith C, Cunningham D,
Starling N, Tait D, Neoptolemos JP and Ghaneh P: Systematic review,
including meta-analysis, on the management of locally advanced
pancreatic cancer using radiation/combined modality therapy. Brit J
Cancer. 96:1183–1190. 2007. View Article : Google Scholar
|
|
5
|
Hazel JJ, Thirlwell MP, Huggins M,
Maksymiuk A and MacFarlane JK: Multi-drug chemotherapy with and
without radiation for carcinoma of the stomach and pancreas: a
prospective randomized trial. J Can Assoc Radiol. 32:164–165.
1981.PubMed/NCBI
|
|
6
|
Klaassen DJ, MacIntyre JM, Catton GE,
Engstrom PF and Moertel CG: Treatment of locally unresectable
cancer of the stomach and pancreas: a randomized comparison of
5-fluorouracil alone with radiation plus concurrent and maintenance
5-fluorouracil – an Eastern Cooperative Oncology Group study. J
Clin Oncol. 3:373–378. 1985.PubMed/NCBI
|
|
7
|
Gastrointestinal tumour study group.
Treatment of locally unresectable carcinoma of the pancreas:
comparison of combined-modality therapy (chemotherapy plus
radiotherapy) to chemotherapy alone. J Natl Cancer Inst.
80:751–755. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Loehrer PJ, Powell ME, Cardenes HR, Wagner
L, Brell JM, Ramanathan RK, Crane CH, Alberts SR and Benson AB;
Eastern Cooperative Oncology Group. A randomized phase III study of
gemcitabine in combination with radiation therapy versus
gemcitabine alone in patients with localized, unresectable
pancreatic cancer: E4201. J Clin Oncol. 26214s(suppl)2008.
|
|
9
|
Chauffert B, Mornex F, Bonnetain F, et al:
Phase III trial comparing intensive induction chemoradiotherapy (60
Gy, infusional 5-FU and intermittent cisplatin) followed by
maintenance gemcitabine with gemcitabine alone for locally advanced
unresectable pancreatic cancer. Definitive results of the 2000–01
FFCD/SFRO study. Ann Oncol. 19:1592–1599. 2008.PubMed/NCBI
|
|
10
|
Epelbaum R, Rosenblatt E, Nasrallah S,
Faraggi D, Gaitini D, Mizrahi S and Kuten A: Phase II study of
gemcitabine combined with radiation therapy in patients with
localized, unresectable pancreatic cancer. J Surg Oncol.
81:138–143. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Krishnan S, Rana V, Janjan NA,
Varadhachary GR, Abbruzzese JL, Das P, Delclos ME, Gould MS, Evans
DB, Wolff RA and Crane CH: Induction chemotherapy selects patients
with locally advanced, unresectable pancreatic cancer for optimal
benefit from consolidative chemoradiation therapy. Cancer.
110:47–55. 2007. View Article : Google Scholar
|
|
12
|
Huguet F, André T, Hammel P, Artru P,
Balosso J, Selle F, Deniaud-Alexandre E, Ruszniewski P, Touboul E,
Labianca R, de Gramont A and Louvet C: Impact of chemoradiotherapy
after disease control with chemotherapy in locally advanced
pancreatic adenocarcinoma in GERCOR phase II and III studies. J
Clin Oncol. 25:326–331. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Moureau-Zabotto L, Phélip JM, Afchain P,
et al: Concomitant administration of weekly oxaliplatin,
fluorouracil continuous infusion, and radiotherapy after 2 months
of gemcitabine and oxaliplatin induction in patients with locally
advanced pancreatic cancer: a Group Coordinateur Multidisciplinaire
en Oncologie Phase II Study. J Clin Oncol. 26:1080–1085. 2008.
|
|
14
|
Nakachi K, Furuse J, Kinoshita T,
Kawashima M, Ishii H, Ikeda M, Mitsunaga S and Shimizu S: A phase
II study of induction chemotherapy with gemcitabine plus S-1
followed by chemoradiotherapy for locally advanced pancreatic
cancer. Cancer Chemother Pharmacol. 66:527–534. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hudson E, Hurt C, Mort D, Brewster AE,
Iqbal N, Joseph G, Crosby TD and Mukherjee S: Induction
chemotherapy followed by chemoradiation in locally advanced
pancreatic cancer: an effective and well-tolerated treatment. Clin
Oncol. 22:27–35. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Reni M, Cereda S, Balzano G, Passoni P,
Rognone A, Zerbi A, Nicoletti R, Mazza E, Arcidiacono PG, Di Carlo
V and Villa E: Outcome of upfront combination chemotherapy followed
by chemoradiation for locally advanced pancreatic adenocarcinoma.
Cancer Chemother Pharmacol. 64:1253–1259. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Crane CH, Abbruzzese JL, Evans DB, et al:
Is the therapeutic index better with gemcitabine-based
chemoradiation than with 5-fluorouracil-based chemoradiation in
locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys.
52:1293–1302. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Magnino A, Gatti M, Massucco P, Sperti E,
Faggiuolo R, Regge D, Capussotti L, Gabriele P and Aglietta M:
Phase II trial of primary radiation therapy and concurrent
chemotherapy for patients with locally advanced pancreatic cancer.
Oncology. 68:493–499. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Girelli R, Frigerio I, Salvia R, Barbi E,
Tinazzi Martini P and Bassi C: Feasibility and safety of
radiofrequency ablation for locally advanced pancreatic cancer. Br
J Surg. 97:220–225. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Casadei R, Ricci C, Pezzilli R, Serra C,
Calculli L, Morselli-Labate AM, Santini D and Minni F: A
prospective study on radiofrequency ablation locally advanced
pancreatic cancer. Hepatobiliary Pancreat Dis Int. 9:306–311.
2010.PubMed/NCBI
|
